A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition where fat builds up in the liver, which can lead to inflammation and long-term scarring. The SYNERGY-Outcomes trial aims to find out if two newer medicines, tirzepatide and retatrutide, can protect the liver and prevent severe complications like liver failure. About 4,500 adults with signs of liver scarring will join this study. Participants are randomly chosen by a computer to receive regular doses of retatrutide, tirzepatide, or an inactive dummy treatment called a placebo. The main trial lasts around four and a half years and includes roughly 25 to 30 hospital visits for health checks, scans, and blood tests. Afterwards, participants may join an optional two-year extension where everyone receives an active medication.
De un vistazo
¿De qué trata este estudio?
Metabolic dysfunction-associated steatotic liver disease, or MASLD for short, happens when extra fat builds up inside liver cells. For many people, this causes no noticeable symptoms at first. However, over time, the fat can irritate the liver, leading to inflammation and stiff scar tissue. If left unchecked, this scarring can slowly progress to severe liver damage, known as cirrhosis, or even liver failure.
Currently, the main treatments for MASLD involve lifestyle changes such as eating a balanced diet, exercising, and losing weight, but there are few approved medicines specifically designed to reverse or stop this damage. This clinical trial is testing two modern medications, tirzepatide and retatrutide. Both work by copying natural gut hormones that help control blood sugar, decrease appetite, and reduce fat stored in organs like the liver.
The main goal of the SYNERGY-Outcomes study is to see whether these medicines can stop major liver problems from developing in adults who already have significant liver fat and stiffness. By comparing these treatments against a dummy medicine (a placebo), researchers hope to find reliable evidence to help guide future care for thousands of people living with liver disease.
Puntos clave
- The study tests whether tirzepatide or retatrutide can prevent severe liver complications in people with fatty liver disease (MASLD).
- It is open to adults with liver fat and moderate scarring, measured using non-invasive scans and blood tests.
- Participation lasts about four and a half years with roughly 25 to 30 clinic visits.
- Participants are randomly assigned to receive tirzepatide, retatrutide, or an inactive placebo.
- An optional two-year extension offers access to active medication for everyone who completes the main study.
¿Quién puede ser elegible?
This trial is for adults aged 18 and over who have a build-up of fat in their liver alongside early-to-moderate liver scarring (fibrosis). Doctors measure this using simple, non-invasive tests such as specialised ultrasound scans (like a FibroScan) and blood tests, rather than needing a surgical liver biopsy. To take part, you must also have a body mass index (BMI) of 25 or higher, which means carrying extra body weight.
You will not be able to join if your liver disease has already reached an advanced, failing stage—for example, if you have had fluid build-up in your tummy (ascites) or bleeding veins in your gullet. People with other liver conditions, such as viral hepatitis, cannot take part.
Additionally, the study is not suitable for people with type 1 diabetes, those whose blood sugar levels are very high (HbA1c over 10%), or anyone who has unintentionally lost more than 11 pounds (about 5 kg) in the three months before joining.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- I am aged 18 or older.
- I have been told I have fatty liver disease (MASLD/NAFLD) with some liver stiffness or scarring.
- My body mass index (BMI) is 25 or higher.
- I do not have type 1 diabetes.
- I have not had serious liver failure complications (such as fluid build-up in the tummy or swollen veins in the gullet).
- I have not lost more than 11 pounds (5 kg) without trying in the last three months.
¿En qué consiste la participación?
Taking part in the study lasts around four and a half years (approximately 224 weeks). During this time, you will visit a specialist hospital clinic about 25 to 30 times. At these visits, doctors and nurses will check your general health, take blood and urine samples, and carry out periodic liver scans to see how your liver is responding.
You will be randomly assigned by a computer to receive weekly injections of either retatrutide, tirzepatide, or a dummy treatment (placebo). Neither you nor your study doctor can choose which one you receive. You will be shown how to give these injections yourself at home using an easy-to-use pen device. Once the main study ends, eligible participants can choose to join an optional two-year extension study, where everyone receives an active medicine.
Riesgos y beneficios potenciales
Locations (563)
- MFA Clinical ResearchCódigo postal verificadoTuscaloosa, United States· Reclutamiento
- The Institute for Liver Health II dba Arizona Clinical Trials - ChandlerCódigo postal verificadoChandler, Estados Unidos· Reclutamiento
- Spectrum Research InstituteCódigo postal verificadoGilbert, United States· Reclutamiento
- The Institute for Liver Health II dba Arizona Liver Health - PeoriaCódigo postal verificadoPeoria, Estados Unidos· Reclutamiento
- Epic Medical Research-Sun CityCódigo postal verificadoSun City, Estados Unidos· Reclutamiento
- The Institute for Liver Health II dba Arizona Clinical Trials - TucsonCódigo postal verificadoTucson, Estados Unidos· Reclutamiento
- Del Sol Research Management, LLCCódigo postal verificadoTucson, Estados Unidos· Reclutamiento
- Arkansas Gastroenterology - North Little RockCódigo postal verificadoNorth Little Rock, United States· Reclutamiento
- San Fernando Valley Health InstituteCódigo postal verificadoCanoga Park, United States· Reclutamiento
- Ark Clinical Research - Fountain ValleyCódigo postal verificadoFountain Valley, Estados Unidos· Reclutamiento
- Fresno Clinical Research CenterCódigo postal verificadoFresno, United States· Reclutamiento
- UCSD - Altman Clinical and Translational Research Institute (ACTRI)Código postal verificadoLa Jolla, Estados Unidos· Reclutamiento
Preguntas comunes
What is MASLD?
MASLD stands for metabolic dysfunction-associated steatotic liver disease. It is the medical term for fat building up in the liver in people who may also have weight, cholesterol, or blood sugar concerns. It used to be commonly called non-alcoholic fatty liver disease (NAFLD).
¿Qué es un placebo?
A placebo looks identical to the real medicine and is given the same way, but it contains no active ingredients. It helps researchers clearly see whether the real medicines work better than having no medication at all.
Will I have to pay for the treatment?
No. All study-related medicines, tests, and clinic appointments are provided free of charge, and trial organisers often help cover reasonable travel expenses to visits.
Do I have to have a liver biopsy to join?
No. This study uses non-invasive tests, such as simple blood tests and painless ultrasound-based scans, to check the fat and stiffness in your liver.
Can I leave the study early if I change my mind?
Yes. You can withdraw from the study at any time, for any reason, and your regular medical team will continue to look after your health as normal.
Cómo obtener más información
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
¿Interesado en participar?
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.